Sector Expert: Henry McCusker

Scimitar Equity

Image: Henry McCusker

Analyst, journalist and publisher Henry McCusker has worked as an independent equity research analyst, digital media publisher and online news portal developer since 2001. He is founder and director of research for Scimitar Equity LLC, which aggregates regenerative medicine and cell therapy news to provide customized, vetted, relevant and in-depth coverage of cell therapy, regenerative medicine and stem cell research companies and investing funds. McCusker was the vice president of strategic planning and communication at Curis Inc. and worked with Hembrecht & Quist Capital Managment (now Tekla Capital Management LLC) focusing on healthcare investments. He also founded LifeScience Economics, a research and analytics firm. A former military officer, McCusker has been an adjunct professor at Boston University and Golden Gate University.



Recent Quotes

"ATHX has partnered to develop cell therapy treatments in Japan."

— Henry McCusker, RegMed Investors (1/8/16)
more >

"BCLI has been awarded an additional grant of $735K from Israel's OCS."

— Henry McCusker, RegMed Investors (11/30/15)
more >

"MSB is planning an IPO in the U.S. under the symbol MESO and is now reporting in U.S. dollars."

— Henry McCusker, RegMed Investors (10/30/15)
more >

"STEM has authorization to expand its Phase 2 SCI trial into Canada."

— Henry McCusker, RegMed Investors (6/18/15)
more >

"MSB's results have shown its proprietary allogeneic mesenchymal precursor cells have significant promise."

— Henry McCusker, RegMed Investors (5/12/15)
more >

"STEM expects to release six-month interim Phase 2 data later this year."

— Henry McCusker, RegMed Investors (4/16/15)
more >

"ATHX and Chugai have announced a partnership for MultiStem."

— Henry McCusker, RegMed Investors (3/2/15)
more >

"ATHX's stock should benefit from the £2M grant from Innovate UK."

— Henry McCusker, RegMed Investors (1/22/15)
more >



Due to permission requirements, not all quotes are shown.